![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
BD Johnson, GH Hockerman, T Scheuer and WA Catterall
Department of Pharmacology, University of Washington School of Medicine, Seattle 98195-7280, USA.
The phenylalkylamines (-)-D888, verapamil, and D600, cause voltage- and use-dependent block of L-type Ca2+ channels and differ from each other only in the number of methoxy groups on each of their two terminal phenyl rings. To study the effects of mutations in the phenylalkylamine receptor site on block by these drugs, wild-type and mutant Ca2+ channels were transiently expressed in the tsA-201 clone of human embryonic kidney 293 cells. The combined mutations Y1463A, A1467S, and I1470A (mutant YAI) in transmembrane segment S6 of domain IV of the alpha 1c subunit disrupted block by all three phenylalkylamines. Surprisingly, although this mutation reduced both resting block at -60 mV and depolarized block at +10 mV by (-)-D888, resting and depolarized block by verapamil and D600 were relatively unaffected. In contrast, for all three drugs, use-dependent block during repetitive stimulations was sharply reduced, and the rate of recovery from depolarized block was accelerated for YAI channels. Thus, the effects of the YAI mutation on apparent affinity were specific to (-)-D888, whereas effects on the kinetics of block were observed for all three drugs. Additional experiments with substitution of phenylalanine for Y1463 suggested that (-)-D888 affinity is specifically sensitive to removal of the hydroxyl group of Y1463, whereas effects on the kinetics of block by all three phenylalkylamines require larger molecular changes, perhaps related to residue size and hydrophobicity. Analysis of the data using a state- dependent model of drug block suggests that these kinetic differences are caused by both changes in drug access to the receptor site and affinity for binding to the inactivated state of the channel. The different effects of the YAI mutations on the actions of (-)-D888, verapamil, and D600 indicate that these residues interact differently with these closely related drugs.
This article has been cited by other articles:
|
|
 |
|
  A. Husch, S. Hess, and P. Kloppenburg Functional Parameters of Voltage-Activated Ca2+ Currents From Olfactory Interneurons in the Antennal Lobe of Periplaneta americana J Neurophysiol, January 1, 2008; 99(1): 320 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Freeze, M. M. McNulty, and D. A. Hanck State-Dependent Verapamil Block of the Cloned Human Cav3.1 T-Type Ca2+ Channel Mol. Pharmacol., August 1, 2006; 70(2): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Dreker and S. Grissmer Investigation of the Phenylalkylamine Binding Site in hKv1.3 (H399T), a Mutant with a Reduced C-Type Inactivated State Mol. Pharmacol., October 1, 2005; 68(4): 966 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dilmac, N. Hilliard, and G. H. Hockerman Molecular Determinants of Frequency Dependence and Ca2+ Potentiation of Verapamil Block in the Pore Region of Cav1.2 Mol. Pharmacol., November 1, 2004; 66(5): 1236 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dilmac, N. Hilliard, and G. H. Hockerman Molecular Determinants of Ca2+ Potentiation of Diltiazem Block and Ca2+-Dependent Inactivation in the Pore Region of Cav1.2 Mol. Pharmacol., August 1, 2003; 64(2): 491 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Lipkind and H. A. Fozzard Molecular Modeling of Interactions of Dihydropyridines and Phenylalkylamines with the Inner Pore of the L-Type Ca2+ Channel Mol. Pharmacol., March 1, 2003; 63(3): 499 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bodi, S. E. Koch, H. Yamaguchi, G. P. Szigeti, A. Schwartz, and G. Varadi The Role of Region IVS5 of the Human Cardiac Calcium Channel in Establishing Inactivated Channel Conformation. USE-DEPENDENT BLOCK BY BENZOTHIAZEPINES J. Biol. Chem., May 31, 2002; 277(23): 20651 - 20659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gage, S. G. Rane, G. H. Hockerman, and T. J. Smith The Virally Encoded Fungal Toxin KP4 Specifically Blocks L-Type Voltage-Gated Calcium Channels Mol. Pharmacol., April 1, 2002; 61(4): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Grace and A.J. Camm Voltage-gated calcium-channels and antiarrhythmic drug action Cardiovasc Res, January 1, 2000; 45(1): 43 - 51. [Full Text] [PDF]
|
|
|
|
|
|
H. K. Motoike, I. Bodi, H. Nakayama, A. Schwartz, and G. Varadi A Region in IVS5 of the Human Cardiac L-type Calcium Channel Is Required for the Use-dependent Block by Phenylalkylamines and Benzothiazepines J. Biol. Chem., April 2, 1999; 274(14): 9409 - 9420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kraus, S. Hering, M. Grabner, D. Ostler, and J. Striessnig Molecular Mechanism of Diltiazem Interaction with L-type Ca2+ Channels J. Biol. Chem., October 16, 1998; 273(42): 27205 - 27212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Hockerman, B. D. Johnson, M. R. Abbott, T. Scheuer, and W. A. Catterall Molecular Determinants of High Affinity Phenylalkylamine Block of L-type Calcium Channels in Transmembrane Segment IIIS6 and the Pore Region of the alpha 1 Subunit J. Biol. Chem., July 25, 1997; 272(30): 18759 - 18765. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
